Kiniksa Pharmaceuticals International (KNSA) Equity Average (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Equity Average for 5 consecutive years, with $551.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 25.99% year-over-year to $551.5 million, compared with a TTM value of $551.5 million through Dec 2025, up 25.99%, and an annual FY2025 reading of $503.0 million, up 14.68% over the prior year.
- Equity Average was $551.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $515.2 million in the prior quarter.
- Across five years, Equity Average topped out at $551.5 million in Q4 2025 and bottomed at $159.9 million in Q2 2022.
- Average Equity Average over 5 years is $370.0 million, with a median of $408.4 million recorded in 2023.
- The sharpest move saw Equity Average plummeted 36.87% in 2022, then soared 150.75% in 2023.
- Year by year, Equity Average stood at $199.5 million in 2021, then soared by 95.49% to $390.1 million in 2022, then rose by 8.18% to $422.0 million in 2023, then increased by 3.73% to $437.7 million in 2024, then rose by 25.99% to $551.5 million in 2025.
- Business Quant data shows Equity Average for KNSA at $551.5 million in Q4 2025, $515.2 million in Q3 2025, and $476.2 million in Q2 2025.